

October 1, 2018

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director,

President and Chief Executive Officer

**Completion and Monthly Exercise Status of the 45<sup>th</sup> Stock Acquisition Rights (with Exercise Price Revision Clauses)  
 Issued by way of Third Party Allotment**

TOKYO, Japan, October 1, 2018—SymBio Pharmaceuticals Limited (JASDAQ: 4582) announces the monthly exercise status for September of 45<sup>th</sup> Stock Acquisition Rights issued and that the exercise of all 45<sup>th</sup> stock acquisition rights issued and allotted to EVO FUND on April 25, 2018 are completed as of today..

**I . Monthly Exercise Status**

(1) Name of stock acquisition rights	SymBio Pharmaceuticals Limited 45 <sup>th</sup> Stock Acquisition Rights
(2) Number of shares delivered for the month	1,220,000 Shares
(3) Number of stock acquisition rights exercised during the month and exercise ratio to the total number of stock acquisition rights issued	1,220,000 Units (Ratio to total 20,000,000 Units Issued : 6.1 %)
(4) Number of unexercised stock acquisition rights at the end of the previous month	1,220,000 Units
(5) Number of unexercised stock acquisition rights at the end of the month	0 Units

**(6) Exercise Status for respective month**

Exercise Date	Number of shares issued		Exercise Price (¥)	Number of stock acquisition rights exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
October 1 (Mon.)	1,220,000	—	132	1,220,000

※Number of issued shares at the end of the previous month : 76,662,224 shares [of which 75shares are treasury shares]

**(7) Status concerning restriction on exercise (Status concerning compliance with exercise restrictions under Article 434 of the Listing Regulations)**

① Total number of shares to deliver upon the exercise of all series of stock acquisition rights	② Number of listed shares at the time of the payment for the issuance	③ Exercise ratio on exercise limit (①/②)
1,220,000 Shares	57,840,724Shares	2.11%

**II . Details of the stock acquisition rights**

(1) Name of stock acquisition rights	SymBio Pharmaceuticals Limited 45 <sup>th</sup> stock acquisition rights
(2) Number of total number of stock acquisition rights issued	20,000,000 units

(3) Exercised number of stock acquisition rights	20,000,000 units
(4) Remaining number of stock acquisition rights	0 units
(5) Amount of fund raised	¥ 2,579,500,000 (approximate amount after deducting costs and expenses)
(6) Allottee	EVO FUND
(7) Date of Allotment	April 25, 2018

III. Amount of paid-in capital and shares outstanding as of October 1, 2018

(1) Number of issued shares	77,882,224 shares
(2) Amount of paid-in capital	¥ 12,482,160,865

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.